share_log

Eli Lilly and Co | 8-K: Eli Lilly and Co Reports First-Quarter 2024 Financial Results

Eli Lilly and Co | 8-K: Eli Lilly and Co Reports First-Quarter 2024 Financial Results

礼来 | 8-K：礼来公布2024年第一季度财务业绩
美股sec公告 ·  04/30 07:05
Moomoo AI 已提取核心信息
Eli Lilly and Co announced robust financial results for the first quarter of 2024, with a significant 26% increase in revenue to $8.77 billion compared to the same period in 2023. The growth was primarily driven by strong sales of Mounjaro, Zepbound, Verzenio, and Jardiance. The company also reported a 66% increase in reported earnings per share (EPS) to $2.48 and a 59% increase in non-GAAP EPS to $2.58. Eli Lilly raised its full-year revenue guidance by $2 billion and increased its reported EPS guidance by $1.25, now expecting it to be in the range of $13.05 to $13.55, with non-GAAP EPS guidance also raised by $1.30 to be between $13.50 and $14.00. The company's pipeline showed positive progress, including positive results from Phase 3 trials of tirzepatide for obstructive sleep apnea and submissions for mirikizumab for Crohn's disease in the U.S. and EU. Additionally, the company is expanding its manufacturing capacity to meet the high demand for its incretin medicines. The financial results were released on April 30, 2024, and included a press release detailing the quarter's performance and future outlook.
Eli Lilly and Co announced robust financial results for the first quarter of 2024, with a significant 26% increase in revenue to $8.77 billion compared to the same period in 2023. The growth was primarily driven by strong sales of Mounjaro, Zepbound, Verzenio, and Jardiance. The company also reported a 66% increase in reported earnings per share (EPS) to $2.48 and a 59% increase in non-GAAP EPS to $2.58. Eli Lilly raised its full-year revenue guidance by $2 billion and increased its reported EPS guidance by $1.25, now expecting it to be in the range of $13.05 to $13.55, with non-GAAP EPS guidance also raised by $1.30 to be between $13.50 and $14.00. The company's pipeline showed positive progress, including positive results from Phase 3 trials of tirzepatide for obstructive sleep apnea and submissions for mirikizumab for Crohn's disease in the U.S. and EU. Additionally, the company is expanding its manufacturing capacity to meet the high demand for its incretin medicines. The financial results were released on April 30, 2024, and included a press release detailing the quarter's performance and future outlook.
礼来公司公布了2024年第一季度的强劲财务业绩，与2023年同期相比，收入大幅增长了26％，达到87.7亿美元。增长主要是由Mounjaro、Zepbound、Verzenio和Jardiance的强劲销售推动的。该公司还报告称，报告的每股收益（EPS）增长了66％，至2.48美元，非公认会计准则每股收益增长了59％，至2.58美元。礼来将其全年收入预期上调了20亿美元，并将公布的每股收益预期上调了1.25美元，目前预计将在13.05美元至13.55美元之间，非公认会计准则每股收益预期也上调了1.30美元，至13.50美元至14.00美元之间。该公司的产品线显示出积极进展，包括替塞帕肽治疗阻塞性睡眠呼吸暂停的3期试验的积极结果，以及在美国和欧盟提交的治疗克罗恩病的米利珠单抗的申请。此外，该公司正在扩大其制造能力，以满足对其肠促胰岛素药物的高需求。财务业绩于2024年4月30日发布，其中包括一份详细介绍该季度业绩和未来展望的新闻稿。
礼来公司公布了2024年第一季度的强劲财务业绩，与2023年同期相比，收入大幅增长了26％，达到87.7亿美元。增长主要是由Mounjaro、Zepbound、Verzenio和Jardiance的强劲销售推动的。该公司还报告称，报告的每股收益（EPS）增长了66％，至2.48美元，非公认会计准则每股收益增长了59％，至2.58美元。礼来将其全年收入预期上调了20亿美元，并将公布的每股收益预期上调了1.25美元，目前预计将在13.05美元至13.55美元之间，非公认会计准则每股收益预期也上调了1.30美元，至13.50美元至14.00美元之间。该公司的产品线显示出积极进展，包括替塞帕肽治疗阻塞性睡眠呼吸暂停的3期试验的积极结果，以及在美国和欧盟提交的治疗克罗恩病的米利珠单抗的申请。此外，该公司正在扩大其制造能力，以满足对其肠促胰岛素药物的高需求。财务业绩于2024年4月30日发布，其中包括一份详细介绍该季度业绩和未来展望的新闻稿。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息